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Opinion statement
Organ preservation has been increasingly utilised in the management of muscle-invasive
bladder cancer. Multiple bladder preservation options exist, although the approach of
maximal TURBT performed along with chemoradiation is the most favoured. Phase III trials
have shown superiority of chemoradiotherapy compared to radiotherapy alone. Concurrent
chemoradiotherapy gives local control outcomes comparable to those of radical surgery, but
seemingly more superior when considering quality of life. Bladder-preserving techniques
represent an alternative for patients who are unfit for cystectomy or decline major surgical
intervention; however, these patients will need lifelong rigorous surveillance. It is important
to emphasise to the patients opting for organ preservation the need for lifelong bladder
surveillance as risk of recurrence remains even years after radical chemoradiotherapy
treatment. No randomised control trials have yet directly compared radical cystectomy with
bladder-preserving chemoradiation, leaving the age-old question of superiority of one
modality over another unanswered. Radical cystectomy and chemoradiation, however, must
be seen as complimentary treatments rather than competing treatments. Meticulous patient
selection is vital in treatment modality selection with the success of recent trials within the
field of bladder preservation only being possible through this application of meticulous
selection criteria compared to previous decades. A multidisciplinary approach with radiation
oncologists, medical oncologists, and urologists is needed to closely monitor patients who
undergo bladder preservation in order to optimise outcomes.
Introduction
Bladder tumours are the 2nd most common genitouri-
nary tumours and the 9th most common cause of
cancer-associated morbidity worldwide [1]. In the USA
for 2015, it is estimated that 74,000 new cases of bladder
cancer (BC) will be diagnosed, and there will be an
estimated 16,000 cases of BC-associated mortality [2].
It signifies the most common urinary tract malignancy,
with a metastatic bladder cancer median survival rate
that seldom exceeds 15 months. A changing age distri-
bution of western societies and a progressing bequest of
cigarette smoking have meant that bladder-related can-
cers have accelerated, becoming a significant cause of
death [3].
When comparing the 5-year relative survival rates of
themost commonUKmalignancies from 1970 to 2009,
all malignancies show a rise in relative survival across
the years, apart from BC which shows a 12.5 % reduc-
tion in relative survival from 1991 to 2009 (Fig. 1) [4].
The management of muscle-invasive bladder cancer
(MIBC) remains a multifactorial challenge as well as
the eradication of local disease, the eradication of
micrometastasis, and finally the maintenance of an op-
timal quality of life.
Considering that themean age at diagnosis is 70, and
the single most significant risk factor is smoking, many
patients present with existing co-morbidities, rendering
certain interventions highly risky and therefore present-
ing limited options for treatment. At initial presentation,
30 % of patients are diagnosed with a muscle-invasive
tumour. From the remainder of patients that had been
diagnosed with a non-muscle invasive tumour at pre-
sentation, 30 % go on to develop muscle-invasive dis-
ease during follow-up [5]. With the highest
predisposition to relapse of any malignancy, patients
with BC require regular surveillance and close follow-
up during and, more significantly, in succeeding therapy
[6]. The management of bladder tumours has remained
largely unchanged over the last few decades. The as-
sumed gold standard treatment for organ-confined
MIBC is radical cystectomy (RC), with bilateral dissec-
tion of pelvic lymph nodes (PLND). Although RC aims
to be curative, at least half of patients with muscle-
invasive disease develop metastasis within a 2-year peri-
od and subsequently die [7]. Furthermore, patients un-
dergoing RC will often be left with a replacement
voiding system which uses autologous segments of gas-
trointestinal tissue [8]. This is often achieved through
ileal conduit urinary diversion, orthotopic bladder sub-
stitution or continent cutaneous diversion [9, 10].
Whilst radical extirpation of the bladder can be success-
ful, from an oncological perspective, substantial mor-
bidity is associated with enteric interposition of gastro-
intestinal tissue within the urinary tract [11, 12]. Surgical
intervention itself requires procedures on the urinary
and gastrointestinal tracts which are associated with
complication rates of approximately 61 % [13]. The
average post-operative length of stay ranges from 7 to
14 days with a post-operative 90-day readmission rate of
32 % as demonstrated by Aghazadeh et al. [14–16]. In a
similar study, Goodney et al. reported a 30-day readmis-
sion rate of 21 %, the second highest rate of any surgical
procedure, only surpassed by mitral valve replacement
(22 %) [16].
Despite continent reconstruction of the urinary tract
using cutaneous reservoirs or orthotopic diversions be-
ing a stepup from ileal conduit urinary diversion, a
Fig. 1. Age-standardized 5-year relative survival rates, England and Wales 1971–1995, England 1996–2009 based on type of cancer
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limited number of patients in practice will have conti-
nent urinary reconstruction [17]. Moreover, whilst the
use of tissue engineering in the field of bladder recon-
struction post-cystectomy shows great potential, its clin-
ical application in mainstream urological practice seems
still quite a way off [18]. The use of bladder-sparing
approaches with regards to MIBC has been extensively
investigated over the past two decades. These ap-
proaches have been developed to address the needs of
two main cohorts: patients with severe medical co-
morbidities for whom a radical surgery is too high risk
and patients with limited disease who wish to avoid
radical surgery.
The general consensus is that single-modality blad-
der-preserving approaches consisting of chemotherapy,
radiotherapy or transurethral resection of bladder tu-
mour (TURBT) are inferior and often yield inferior re-
sults for local tumour control and long-term survival in
MIBC. Consequently, dual/trimodality regimens have
been used to attempt to replicate the outcomes of RC,
whilst avoiding the morbidity and impact on quality of
life associated with radical therapy. The trimodality ap-
proach involves an extensive TURBT, attempting to
achieve complete resection. Complete resection may
not always be possible, and incomplete resection is
associated with a reduced disease-free survival [19]. In-
duction therapy then follows with surveillance cystosco-
py and biopsy to assess clinical response. Complete
responders will progress to chemoradiation whilst
non-responders will undergo cystectomy.
Historically, bladder-sparing approaches were initial-
ly used in patients who were not candidates for surgery;
however, despite this poorly selected population, the 5-
year local control rate for these patients was 20–40 %
whilst overall survival (OS) was 50 % [20–23]. These
results were always seen to be inferior to surgery, and
therefore their role in the immediate management of BC
was rarely explored in a more selective cohort of pa-
tients.
Phase I and II trials in the 1980s showed that meta-
static BCs are chemosensitive, fostering hope of cure.
Various treatment algorithms have been proposed to
aid in patient selection for bladder preservation and
their risk stratification towards appropriate treatment
options—no doubt the most vital factors in BCmanage-
ment [24]. Although accumulated data over the last
20 years has suggested that concomitant chemoradia-
tion in MIBC gives equivalent results to those of RC, it
has never been formally compared in a randomised
control trial.
The difficulty in achieving both complete treatment
response whilst ensuring bladder function remains ac-
ceptable and has driven urologists and oncologists to
work together to develop multimodal approaches to
MIBC. Here, we present a review of the current literature
related to the bladder sparing approaches for MIBC.
Radical TUR
TUR involves the transmural resection of the bladder
wall and resecting all visible tumours as far out as the
perivesical connective tissue [25]. This extensive resec-
tion comes with significant risks including bladder per-
foration and increased risk of tumour dissemination
through extravesical seeding [26].
Primarily, the rationale behind radical TUR as the
only treatment is the discovery of pT0 at RC in those
previously only treated with TUR before surgery. Studies
have shown a 910 % incidence of pT0 at RC [27–30].
Furthermore, 42% of those with cT2a disease have been
shown to have pT0 disease after visibly completing TUR
[30]. Even those with pT0 are not all truly free of disease
as recurrence-free survival (RFS) has been reported as 92
and 86 % at 5 and 10 years, respectively [28].
The overall consensus amongst the majority of
experts is that TUR alone is inadequate for a diagno-
sis of MIBC. The reasons behind this are extensive;
however, one factor deemed significant is the high
rate of upstaging at RC. Studies have demonstrated
upstaging from cT2 to pT3 as high as 39.7 % [31]
with lymph node metastasis at the time of
cystectomy at 23 % as reported in several series
[28, 31, 32]. Patient selection is therefore vital and
is often used as a last resort for those unwilling or
unfit to undergo more aggressive treatment. Al-
though limited data exists for long-term outcomes
of radical TUR, two prospective studies have been
the basis of radical TUR monotherapy with distinc-
tive results (Table 1).
It is vital to adopt appropriate and accurate pa-
tient selection when choosing candidates which may
have successful outcomes from radical TUR as de-
tailed in the above studies. Ideal candidates boasted
no evidence of advanced clinical stage disease, tu-
mours G3 cm, and negative bed biopsies at initial
TUR or negative restaging TUR [33–35].
Surveillance and rigorous follow-up similar to
that in the study by Solsona et al. may not be feasi-
ble. Monotherapy showed inadequacies in patients
who developed disease reoccurrence, and, therefore,
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for these patients more aggressive treatment with
multimodal approaches could be beneficial. These
patients eventually required RC or further treatment
for residual disease/local relapse [33, 34]. BCs are
known to have the highest susceptibility of recur-
rence and progression of any malignancy. With such
high odds of recurrence, BC has produced the most
expensive management protocol of any malignancy,
costing the National Health Service approximately
£55.39 million in the UK per annum [6].
Radiotherapy
Conventionally, radiotherapy is administered externally
in a typical dose schedule of 64 Gy in 32 fractions or
hypofractionated schedules such as 55 Gy in 20 frac-
tions, both shown to be equally as effective in the long
term [36••]. Although a clear dose-response relation-
ship has not been identified, studies including a
multivariant analysis have shown poorer outcomes
when using doses less than 57.5 Gy [37, 38]. It is im-
portant, however, to appreciate that increasing dosages
of radiotherapy is closely linked with toxicity, but the
majority of modern regimens are tolerated well and
long-term bladder function is seldom effected [39]. De-
spite its merits, however, its use has declined markedly
since the 1980s and radiotherapy alone is now used only
in circumstances where other treatment modalities have
failed, or in advanced disease. It is important to note that
radiotherapy is seldom used alone and that the majority
of patients have often already undergone prior TUR.
Although surgery is considered the standard of care
in the majority of patients, considerable interest in blad-
der preservation has led to radiotherapy re-emerging as
an effective alternative, particularly in patients who are
not fit for radical surgery. Due to the cohorts that are
treated with radiotherapy, it is often difficult to compare
outcomes of radiotherapy with surgery. Patients under-
going radical radiotherapy in comparison with surgical
candidates often have multiple co-morbidities with
worse prognostic factors and poorer performance status-
es [40, 41]. It is for these reasons that studies have
reported relatively high rates of incomplete response
and local recurrences that reach up to 50 % [42].
Studies have demonstrated outcomes that remain
inferior to multimodal treatment modalities, with a 5-
year overall survival (OS) of 26–50 % and local control
rates of approximately 50 % [22, 43–49].
Pollack et al. assessed response to radiotherapy in
different tumour stages and reported a 5-year OS for
T2 to be 40–59 % and 0–50 % for T3 [45]. In a similar
study, Pollack et al. reported local long-term control
rates after radiotherapy alone in T3b at 27 % [20].
Factors that have been found to be statistically signifi-
cant in prognosticating local failure are tumour multi-
plicity, ureteric obstruction and higher T stage [22].
Shipley et al. evaluated data from 55 patients treated
with radiotherapy alone in order to identify factors as-
sociated with tumour radio responsiveness. Sixty-seven
percent of patients presented with T2 or T3 tumours
with the remainder of patients having T4 tumours. OS
after 5 years was 28 %; however, when comparing pa-
tients who possessed T2/3 with those having T4 disease,
survival after 5 years was 45 and 9 %, respectively. The
T2/3 group demonstrated that the most vital prognostic
factor was histological finding of tumour on papillary
surface, in the absence of urethral obstruction, and in
less advanced clinical stages, factors that were similarly
found by Pollack et al. [19, 45].
It is important to mention, however, that both
population-based studies and large surgical and
radiotherapy-based series have shown similar long-
term survival rates and no survival difference linked to
mode of treatment [28, 48, 50]. Additionally, the vast
majority of these large-scale surgical series have popula-
tion medians which are well below the disease popula-
tion, signifying its lack of application in patients with
invasive bladder disease [28]. In a large population-
based series, Munro et al. investigated the outcomes of
458 patients with MIBC undergoing RC versus radio-
therapy. OS was similar in the two groups, 22 % for
those undergoing radiotherapy, and 24 % in the group
undergoing RC [51].
Although chemoradiotherapy has much better out-
comes as a treatment option in comparison with radio-
therapy alone, a small proportion of patients will not be
candidates for dual therapy and radiotherapy alonemay
be the only treatment option available. A highly conclu-
sive study by James et al. demonstrated that chemora-
diotherapy significantly improved loco-regional control
of BC with no significant increase in adverse events
compared with radiotherapy alone. They also provided
evidence, which would suggest that RT alone does have
at least some curative potential. Loco-regional DFS at 2
and 5 years was 54 and 35 %, respectively [36••].
Chemotherapy
Chemotherapy has been used for decades in the man-
agement of MIBC as neoadjuvant or adjuvant adjuncts
to primary RC or as an organ preservation treatment.
This has shown to reduce the risk of micrometastasis,
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improving survival [52, 53]. A recent international
multicentre-randomised phase III trial investigated the
use of neoadjuvant cisplatin, methotrexate and vinblas-
tine (CMV) chemotherapy in patients withMIBC treated
by cystectomy and/or radiotherapy [54]. This trial dem-
onstrated long-term statistically significant reduction in
risk of death and a 6 % increase in a 10-year survival
after CMV therapy, compared with radiotherapy or RC
alone. The addition of paclitaxel to GC demonstrated
superiority through a higher response rate as well as
survival benefit which did not reach statistical signifi-
cance [55]. Chemotherapy alone does not play any role
in the management of MIBC.
Synchronous Chemoradiation
The first bladder preservation studies were conducted in
the early 1980s and were found to demonstrate encour-
aging results [47, 48, 56–59]. Rationale that supports the
addition of chemotherapy to radiotherapy is based on
four main principals. Firstly, the evidence of
micrometastasis exists concurrently with invasive BC.
In a study of 367 individuals at autopsy, 68 % demon-
strated distant metastasis, with frequency of metastasis
increasing with tumour stage as one would expect (pT2
36%, pT3a 45%, pT3b 69% and pT4 79%) [60].This is
supported by the high probability of consequent distant
metastasis post-cystectomy or radiotherapy alone by
approximately 50 % after 2 years [28]. This suggests that
combination therapy would reduce the likelihood of
distant metastasis by tackling micrometastatic disease.
Secondly, the use of radiotherapy on its own can cause
the development of vascular sclerosis after a period of
months, thus increasing the likelihood of chemothera-
peutic failure [61]. Thirdly, the prime time to tackle
potential micrometastatic cells is prior to the develop-
ment of gross metastatic disease. Finally are the
radiosensitising properties of certain chemotherapeutic
agents, e.g., gemcitabine, mitomycin C and 5-
fluorouracil [62].
Although a variety of phase I and II trials have dem-
onstrated on the whole good tolerability and feasibility
when assessing chemoradiation, data is still lacking with
very few trials that compare synchronous chemoradia-
tion with radiation alone [42, 48, 63–74]. In fact, the
only randomised trial of this approach before BC2001
[36••] and BCON [75••] was that in 1996 by the Cana-
dian Cancer Society Research Institute [57]. This study
randomised 99 patients to receive radiotherapy of 40 Gy
in 20 fractions alone or radiotherapy with the same
schedule combined with cisplatinum 100 mg/m2 twice
weekly for 3 weeks, followed by elective cystectomy or
further radiotherapy. Those who had received combined
therapy had a significantly lower rate of loco-regional
recurrence compared to those receiving radiotherapy
alone (40 vs 59 % p = 0.026). Statistically, no significant
results were obtained for bladder preservation (70 % vs
36 % p = 0.14) and OS (47 % vs 33 % p = 0.34). Al-
though this is a small study with limited power, the
promising results justified further investigation.
Many studies have evaluated the efficacy of synchro-
nous chemoradiation compared to radiotherapy alone
in tumours arising from primary sites other than the
bladder [76–78]. These studies suggested a substantial
advantage in local control and reduction in odds of
death with combined therapy. One such study is the
UKCCCR, which compared radiotherapy with synchro-
nous chemotherapy in anal cancer [78]. Here, patients
were randomised to receive radiotherapy alone or radio-
therapy with 5-fluorouracil (5FU) by continuous infu-
sion during the first and last weeks of radiotherapy in
addition to mitomycin C on day 1 of the first fraction of
radiotherapy. The significance of this study in the man-
agement of BC came about because of the significant
prevalence of renal impairment amongst the vast major-
ity of BC patients. Cisplatin itself requires an adequate
GFR (960 mL/min) for it to be safely delivered and to
justify its side effect profile [79]. When comparing the
dosing regimen from the Canadian study to our institu-
tion, the vast majority of patients would be deemed
unfit to receive cisplatin at those doses. Our previous
work has demonstrated in a phase I trial that radiother-
apy and concurrent chemotherapy with mitomycin C
and 5FU are feasible with acceptable toxicity in patients
with poor prognosis [73]. Hussain et al. then subse-
quently conducted a phase II trial investigating synchro-
nous chemoradiotherapy with mitomycin C and
infusional 5FU in MIBC. We reported the long-term
toxicity and efficacy results with the optimised regimen.
Patients were administered mitomycin and 5FU for
5 days during weeks 1 and 4 of radiotherapy (55 Gy in
20 fractions). OS was 68 % (12 months), 49 %
(36 months) and 36 % (60 months). It is worth noting
that many patients entering our phase I/II study were
deemed unfit for radical cystectomy. Local and distant
progression free rates were 82 and 86 % at 12 and
24months, respectively, and 79 and 75% at 24months.
We concluded that using multimodality therapy is fea-
sible and safe in patients with poor renal function [80].
Choudhury et al. demonstrated in a phase II trial a high
response rate, durable local control, and acceptable
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toxicity in patients treated with concurrent chemoradio-
therapy using gemcitabine [74].
James et al., following on from the phase I/II study,
demonstrated in a phase III randomised control trial
comparing TURBT with either synchronous chemoradi-
ation (mitomycin C and 5FU) or with radiotherapy
alone (either 55 Gy in 20 fractions over 4 weeks or
64 Gy in 32 fractions over 6.5 weeks) that chemoradia-
tion significantly improved loco-regional control of BC
with no significant increase in adverse events compared
with radiotherapy alone [36••]. This study with a medi-
an follow-up of 69.9 months demonstrated a relative
reduction in loco-regional recurrence of 35 % and al-
most halving of invasive recurrence. At 2 years, loco-
regional DFS was more superior in the chemoradiation
arm compared to radiotherapy alone (67 vs 54 %, re-
spectively). The 5-year OS rate was reported to be 48 %
in the chemoradiation arm compared to 35 % in the
radiotherapy group (HR, 0.82; 95 % CI 0.63–1.09; p =
0.16). Acute toxic effects were also shown not to reach
statistical significance in relation to grades 3 and 4 out-
comes (27.5 % vs 365, p = 0.07). Bladder volume irradi-
ated did however correspond to risk of grade 3 or 4
toxicity. Bladder function, an important contributor to
quality of life, was demonstrated not to be significantly
more impaired in the chemoradiotherapy arm. Good
long-term bladder function and low rates of salvage
cystectomy suggest that the use of chemoradiotherapy
in BC patients who are often frail, with multiple co-
morbidities, appears to be of significant benefit.
Hoskin et al. compared 333 patients with locally
advanced BC in a phase III trial receiving either radio-
therapy alone (schedule of either 55 Gy in 20 fractions
in 4 weeks or 64 Gy in 32 fractions in 6.5 weeks) or
synchronous chemoradiation (carbogen and nicotin-
amide). Chemoradiotherapy showed a non-significant
improvement in the primary end point (cystoscopic
control at 6 months) compared to radiotherapy alone
(81 vs 76 %, p = 0.3) [75••]. Differences in 3-year OS
(59 vs 46 %, p = 0.05), risk of death (14 % lower, p =
0.04) and local relapse (p = 0.05) were significantly in
favour of chemoradiotherapy. There was no difference
in acute bowel and urinary events between the two
groups. Late events only show an increase in morbidity
of grade 2 or worse stool frequency in the treatment
group. This randomised control trial showed that the
use of radiotherapy with concurrent chemotherapy
using nicotinamide and carbogen demonstrates a sched-
ule which has acceptable levels of toxicity, comparable
with what is encountered with radiotherapy alone.
Some therapeutic gain can be concluded from this study,
although non-significant improvements in loco-
regional control may suggest the need for further
radiosensitizers, e.g., cisplatin, different to that of the
hypoxic modification mechanism of nicotinamide and
carbogen.
Taken together, trial data with chemoradiation sug-
gests tolerability in those with poorer renal function and
other existing co-morbidities whether treated with the
North American trimodality approach [72] or the UK
single treatment block [36••]. Other phase III studies
have also demonstrated encouraging results (Table 2).
Quality of Life and Toxicity of Organ Preservation
It is important to mention that perioperative morbidity
and mortality of salvage cystectomy after previous blad-
der chemoradiation is very similar to that of primary
cystectomy [82••]. Recent studies assessing bladder
function in trimodality approaches have demonstrated
in 71 patients (median follow-up 6.3 years) that 75 %
had normally functioning bladders based on
urodynamic studies and 85 % reported no urgency
[83]. It is important to comment that quality of life
and treatment toxicity depend on treatment regimens.
Patient preference and likelihood of treatment success
should drive modality selection. It is however important
to consider the benefit of organ preservation over radial
cystectomy. Several quality of life studies have evaluated
the reconstructive methods of RC. A Japanese study
assessed 85 patients post-reconstructive cystectomy
(orthotopic bladder or ileal conduit) [84]. No significant
difference was found between the modality of recon-
struction; however, when compared with the general
population in the USA, general health and social func-
tioning was significantly lower. Another major concern
following RC is erectile dysfunction; studies have shown
an overall increase in erectile dysfunction, even in nerve-
sparing surgery [85, 86].
Future Directions
In an effort to improve OS and better control of loco-
regional disease, novel approaches have been trialed.
The use of hyperfractionated radiotherapy is one such
approach. The RTOG protocol 07–12 studied the use of
hyperfractionated radiotherapy (twice daily) with con-
current cisplatin therapy which achieved a complete
response of 985 % [87]. Other studies, however, com-
paring chemoradiation with radiation alone using two
fractionation schemes have demonstrated no difference
for loco-regional DFS [36••]. Another novel approach to
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radiotherapy that has been used is image-guided radia-
tion therapy (IGRT): this conformal radiotherapy more
accurately targets tumours in mobile organs like the
bladder [88]. Here, three to four gold markers are im-
planted into the bladder during TURBT and then tracked
during radiotherapy. This allows the radiographer to
ensure the tumour is within the desired radiotherapy
field. However, these plates can often cause pain or fall
out altogether [89]. An alternative to this approach is
using the contrast agent lipodol. This works in the same
way as plate insertion in that during TURBT, lipodol is
injected into the tumour sites and radiotherapy can then
focus its field of treatment. This use of IGRT is ideal as it
can dictate everyday radiotherapy based on the location
of the tumour within the bladder [89]. Bladders will
change in shape and size depending on bowel disten-
tion and the volume of urine in the bladder. Some
agents are currently being investigated for use alongside
radiotherapy. Chakravarti et al. demonstrated that there
is significant correlation between reduced response rate
and HER2/neu overexpression [90]. HER2/neu positivi-
ty can be found in 40–80 % of bladder tumours.
Hussain et al. reported in a multicenter phase II trial
using trastuzumab, carboplatin, gemcitabine and pacli-
taxel in advanced metastatic urothelial carcinoma pa-
tients, with a median time to progression and survival
of 9.3 and 14.1 months, respectively [91]. This study
demonstrated feasibility; however, toxicity rates, espe-
cially cardiac toxicity, were high. Theoretically, there
may therefore be a role of trastuzumab therapy in
HER2/neu-positive bladder tumours in combination
with radiation therapy to further improve on organ
preservation strategies.
Overexpression of EGFR has been found to be signif-
icantly correlated to high tumour stage and poor patient
outcome [92]. EGFR expression, however, as a predictor
Table 2. Phase III chemoradiation trials
Study n Tumour
grade
Methods Complete
response
rate
Results Ref
Hoskin
et al.
333 T2–T4a Radiotherapy (55 Gy in 20 fractions in
4 weeks or 64 Gy in 32 fractions in
6.5 weeks) + nicotinamide (60 or
40 mg/kg given 1.5–2 h before each
fraction) + carbogen (2 % CO2 and
98 % O2 at 15 L/min administered
5 min before and during
radiotherapy) vs radiotherapy alone
81 vs 76 %
(p =
0.3)
3-year overall survival
59 vs 46 % (p = 0.04)
[75••]
Coppin
et al.
99 T2–T4b
N0
Radiotherapy (fractionated continuous
pelvic radiation) + cisplatin
100 mg/m2 at 2-week intervals for
three cycles concurrent with
radiation vs radiotherapy alone
47 vs 31 % 3-year overall survival 47 vs 33 %
5-year locoregional relapse
rate 40 vs 59 % (p = 0.04)
bladder preservation 70 vs
36 %
[57]
James
et al.
360 T2–T4a
N0
Concominant chemoradiotherapy (5FU
500 mg/m2/day during fractions
1–5 and 16–20 and mitomycin C
12 mg/m2 + whole bladder
radiotherapy/modified volume
radiotherapy) vs radiotherapy alone
5-year overall survival 48 vs 35 %
(p = 0.16)
2-year disease-specific survival 67
vs 54 % (p = 0.03)
[36••]
Tunio
et al.
230 T2–T4
N0/Nx
Concomitant chemoradiotherapy with
whole pelvis radiotherapy vs
bladder-only radiotherapy
93 vs 96 %
(p =
0.05)
5-year overall survival 52.9 vs
51 % (p = 0.8)
5-year disease-specific survival
47.1 vs 46.9 % (p = 0.5)
Bladder preservation rates 58.9 vs
57.1 % (p =0.8)
[81•]
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of prognosis, was not independent of stage. The TUXE-
DO trial, a phase I/II trial, is currently underway in UK,
examining combination therapy of cetuximab with 5FU
and mitomycin C with concurrent radiotherapy in
MIBC.
Azuma et al. demonstrated in a recent trial of 134
patients receiving cystectomy or a bladder-preserving
OMC/BOAI-gemcitabine regimen for locally invasive
BC, a15-year OS of 40 % compared to 79.7 % in the
bladder-preserving study arm [93•]. This novel form of
bladder preservation therapy involves using balloon-
occluded arterial infusion (BOAI) of a chemotherapeu-
tic agent (cisplatin/gemcitabine), used concomitantly
with haemodialysis and radiotherapy (known as the
Osaka Medical College [OMC] regimen). This method
maximises the concentration of the chemotherapeutic
agent at the site of the tumour without the systemic
adverse effects experienced by routine chemotherapy
[94]. This method, however, can lead to the develop-
ment of pelvic neuropathy. This bladder-preserving reg-
imen can be curative in patients where both cystectomy
is indicated and in those where curative treatment was
previously not a possibility.
Currently the use of the tumour staging system
(TNM) is insufficient to predict outcome in patients
with BC irrespective of the treatment they receive. Mo-
lecular prognostic markers should be evaluated in
randomised control trials in order to define their role
in clinical outcome measures.
Conclusion
Concurrent chemoradiotherapy may appear to give results equivalent to those
of radical surgery with regards to local control; however, it seems to be more
superior when considering quality of life. It represents an alternative for patients
who decline cystectomy or where cystectomy is contraindicated. No
randomised trial as of yet has directly compared bladder-preserving chemora-
diotherapy with cystectomy, and therefore a definitive answer to the age-old
question of superiority of one modality over other remains unanswered. One
needs to understand that both organ preservation treatment and radical
cystectomy are complimentary treatments rather than competing treatments.
Patients opting for organ preservation need to be counselled about long-term
requirement of cystoscopic surveillance and risk of losing their bladder and
salvage cystectomy even decades after organ preservation therapy. The success of
recent trials within the field of bladder preservation has been possible due to the
meticulous selection criteria applied compared with those from previous de-
cades. Although many chemoradiation protocols exist in the literature, few
direct comparisons exist.
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